The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2009Probing the Neuroprotective Effects of Haploinsufficiency of RanBP2 in Neurotoxicant-induced Experimental Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
A partial deficit in the level of Ran-binding protein-2 (RanBP2) confers neuroprotection to neurons upon aging and deleterious stimuli promoting oxidative stress, a stress... -
Rapid Response Innovation Awards, 2009Identification of Substrates and Development of a Cell Based Assay for LRRK2
Objective/Rationale:
Inherited mutations in a gene called LRRK2 have recently been discovered to cause Parkinson’s disease. The LRRK2 gene encodes an enzyme called a kinase, which is more active when... -
MJFF Research Grant, 2009PD Pre-clinical Model Repository
Objective/Rationale:
The Michael J. Fox Foundation (MJFF) is partnering with The Jackson Laboratory (JAX) to distribute pre-clinical models of Parkinson’s disease (PD). MJFF funding will allow JAX to... -
Rapid Response Innovation Awards, 2009Phase I Trial of Phenylbutyrate to Prevent Progression of Parkinson's Disease
Objective/Rationale:
Parkinson’s disease gets worse over many years because dopamine neurons continue to die. Researchers have discovered a drug that prevents brain deterioration in pre-clinical... -
Rapid Response Innovation Awards, 2009Exploring Serotonergic Cortical Targets for Treatment of Parkinson's Disease Using a Mathematical Disease Model
Objective/Rationale:
Because animal models have limited predictability for clinical outcomes of experimental Parkinson drugs, a complex mathematical model of the interactions between key motor... -
Rapid Response Innovation Awards, 2009The Effect of 4-hydroxy-2-nonenal Modification on Alpha-synuclein Toxicity
Objective/Rationale:
Alpha-synuclein is a protein that is normally produced in the human brain. Compelling evidence suggests that alpha-synuclein can acquire a toxic feature that kills dopamine...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.